Sabra Health Care upgraded to Buy from Hold at Jefferies

Jefferies upgraded Sabra Health Care to Buy from Hold with a price target of $15, up from $11. The analyst sees “significant upside embedded” in the senior housing segment and says the company’s triple-net portfolio has been “significantly de-risked.” As such, Sabra’s current valuation presents a compelling entry point, the analyst tells investors in a research note. The firm expects senior housing occupancy and cash net operating income margin to increase materially over the next two years, driven by macro tailwinds and micro adjustments.